Avalo Therapeutics Inc

NASDAQ:AVTX   3:53:06 PM EDT
5.47
+0.16 (+3.11%)
4:09:15 PM EDT: $5.20 -0.27 (-4.85%)
Earnings Announcements

Avalo Reports Third Quarter Financial Results

Published: 11/07/2022 14:45 GMT
Avalo Therapeutics Inc (AVTX) - Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates.
Avalo Therapeutics Inc- Topline Data Expected in First Half of 2023 From Phase 2 Peak Trial of Avtx-002 in Non-eosinophilic Asthma (nea).
Avalo Therapeutics Inc- Qtrly EPS $0.34.
Revenue is expected to be $4.26 Million
Adjusted EPS is expected to be -$0.77

Next Quarter Revenue Guidance is expected to be $1 Million
Next Quarter EPS Guidance is expected to be -$0.96

More details on our Analysts Page.